

# BIDDLE SAWYER LIMITED

## Directors' Report to the Members

The Directors have pleasure in submitting their 77<sup>th</sup> Report for the year ended 31 March 2023.

### 1. Financial Results for the year ended 31 March 2023

	₹ in Lakhs	
	Year ended 31 March 2023	Year ended 31 March 2022
Revenue from Operations	51,31.09	80,82.46
Profit before Tax	4,00.70	5,60.48
Provision for Tax	1,07.17	31.88
Deferred Tax Charge/ (credit)	-	1,09.25
Net Profit for the year	2,93.53	4,19.35
Closing Surplus/(loss) carried forward	1,72.12	(1,21.41)

## State of Company Affairs

During the year under review, your Company has generated total revenue from operations of ₹ 51,31.09 lakhs as against ₹ 80,82.46 lakhs during the previous year ended 31 March 2022. The net profit for the year ₹ 2,93.53 lakhs, as compared to profit of ₹4,19.35 lakhs during the previous year ended 31 March 2022.

## DIVIDEND

The Directors do not recommend any dividend for the year ended 31 March 2023.

## AUDITORS AND AUDITOR'S REPORT

Members are requested to re-appoint M/s. Cornelius and Davar, Chartered Accountants, as the Auditors of the Company for the ensuing year and fix their remuneration.

The notes on financial statements referred to in the Auditors Report are self-explanatory and do not call for any further comments and explanations. The Auditors' Report does not contain any qualification, reservation or adverse remark.

## DIRECTORS AND KEY MANAGERIAL PERSONNEL

During the year under review, Mr. Sridhar Venkatesh resigned as Director of the Company with effect from 30 November 2022. Mr. Ajay Nadkarni was appointed as Additional Director from 1 December 2022 till conclusion of Annual General Meeting.

In terms of the provisions of the Companies Act, 2013, Mr. B. Akshikar retires from the Board of Directors of the Company by rotation and being, eligible, has offered himself for re-appointment at the ensuing Annual General Meeting.

The Notice convening the forthcoming Annual General Meeting includes the proposal for reappointment of aforesaid Director.

None of the Directors are disqualified for appointment / re-appointment under Section 164 of the Companies Act, 2013.

## DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirements of Section 134(5) of the Companies Act, 2013, your Directors confirm that:

- in the preparation of the annual accounts for the financial year ended 31 March 2023 the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
- the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on 31 March 2023 and of the profit or loss of the Company for that period;
- the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- the Directors have prepared the annual accounts for the financial year ended 31 March 2023 on a going concern basis;
- the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

## OTHER MANDATORY DISCLOSURES

- The Board of Directors met 4 (Four) times during the financial year 2022-23.
- As on 31 March 2023, the Company did not have any Subsidiary / Joint Venture / Associate Company.
- The Company has not granted any loans, provided guarantees or made investments pursuant to the provisions of Section 186 of the Companies Act, 2013, during the financial year 2022-23.
- There were no material changes and commitments affecting the financial position of the Company between the end of financial year and the date of this Report.
- Your Company has not accepted any deposits from the public during the year under review.
- There were no materially significant related party transactions made with the Promoters, Directors or Key Managerial Personnel which may have a potential conflict of Interest of the Company at large.
- No details as required under the provisions of Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are given, as there are no employees drawing remuneration in excess of the prescribed limits.

- There are no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.
- The Company is 100% subsidiary of GlaxoSmithKline Pharmaceuticals Limited ("Parent Company") and all policies including Vigil Mechanism, Risk Management Policy and Internal Financial Control have been adopted on lines of parent Company.

The Company does not have any manufacturing plant or office so Conservation of Energy & Technology Absorption is not applicable. The foreign exchange earnings for the year ended 31 March 2023 was ₹ 44,97.80 lakhs and foreign exchange outgo for the year ended 31 March 2023 was ₹ 5,30.88 lakhs. The foreign exchange earnings for the period ended 31 March 2022 was ₹ 74,00.45 lakhs and foreign exchange outgo for the year ended 31 March 2022 was nil.

## ACKNOWLEDGEMENT

The Board wishes to place on record its gratitude for the assistance and co-operation received from Government, Banks, Authorities, Customer's, Vendors and to all its members for the trust and confidence reposed in the Company.

For and on behalf of the Board of Directors

Mumbai, 10 May 2023

B. Akshikar  
Chairman

# BIDDLE SAWYER LIMITED

Balance Sheet as at 31st March 2023

	Note No.	As at March 31, 2023	As at March 31, 2022
(₹ in lakhs)			
<b>ASSETS</b>			
<b>Non-current assets</b>			
Investment properties	2	2.08	2.08
Financial assets			
(i) Loans	3	-	-
(ii) Other financial assets	3A	2.65	1.45
Current tax assets (net)	25	5,499.8	4,72.84
Deferred tax assets (net)	25	36.43	36.43
Other non-current assets	4	8,01.88	7,32.38
		<b>13,93.02</b>	<b>12,45.18</b>
<b>Current assets</b>			
Inventories	5	22,26.90	21,98.22
Financial Assets			
(i) Cash and cash equivalents	6	5,19.77	5,39.59
(ii) Other financial assets	7	34.69	12,97.17
Other current assets	8	1,15.41	1,15.42
		28,96.77	41,50.40
<b>TOTAL ASSETS</b>		<b>42,89.79</b>	<b>53,95.58</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Equity share capital	9 & 17	96.00	96.00
Other Equity	10	11,81.04	8,87.51
<b>Total equity</b>		<b>12,77.04</b>	<b>9,83.51</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
<b>Financial liabilities</b>			
(i) Borrowings	11	18,10.00	14,60.00
(ii) Other financial liabilities	12	1.35	1.35
Provisions	13	1,25.33	1,25.33
		<b>19,36.68</b>	<b>15,86.68</b>
<b>Current liabilities</b>			
<b>Financial liabilities</b>			
(i) Trade payables	14		
Total outstanding dues of micro enterprises and small enterprises		13.49	18.32
Total outstanding dues of creditors other than micro enterprises and small enterprises		10,50.71	27,87.56
Other current liabilities	15	11.87	19.51
		<b>10,76.07</b>	<b>28,25.39</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>42,89.79</b>	<b>53,95.58</b>

The accompanying notes are an integral part of these financial statements

As per our report of even date attached For and on behalf of the Board

For **CORNELIUS & DAVAR**  
CHARTERED ACCOUNTANTS  
(Firm's Registration No. 101963W)

**B. Akshikar**  
Director  
DIN: 09112346

**J. Chandu**  
Director  
DIN: 09530618

**R. D. DAVAR**  
(PARTNER)  
Membership No. F10620

**R. Mota**  
Company Secretary  
ACS 38473

Place : Mumbai  
Date: May 10, 2023

Place : Mumbai  
Date: May 10, 2023

# BIDDLE SAWYER LIMITED

Statement of profit and loss for the year ended 31st March, 2023

	Note No.	For the year ended March 31, 2023	For the year ended March 31, 2022
(₹ in lakhs)			
Revenue from Operations	18	51,31.09	80,82.46
Other Income	19	0.38	0.79
<b>Total income</b>		<b>51,31.47</b>	<b>80,83.25</b>
<b>Expenses</b>			
Cost of materials consumed	20	33,13.53	58,70.57
Changes in inventories of work-in-progress, stock-in-trade and finished goods	21	1,71.50	1,74.71
Finance costs	22	85.68	45.43
Other expenses	23	11,60.06	14,32.06
<b>Total expenses</b>		<b>47,30.77</b>	<b>75,22.77</b>
<b>Profit/(loss) before exceptional items and tax</b>		<b>4,00.70</b>	<b>5,60.48</b>
Exceptional items		-	-
Profit/(loss) before tax		4,00.70	5,60.48
<b>Income tax expenses</b>			
Current tax	25	1,07.17	31.88
Deferred tax	25	-	1,09.25
<b>Profit / (loss) for the period</b>		<b>2,93.53</b>	<b>4,19.35</b>
<b>Other Comprehensive Income</b>			
Items that will not be reclassified to profit or loss			
Remeasurements of defined benefit liability (asset)		-	-
Income tax relating to items that will not be reclassified to profit or loss		-	-
<b>Total Comprehensive Income / (loss) for the period</b>		<b>2,93.53</b>	<b>4,19.35</b>
<b>Profit / (loss) attributable to:</b>			
Owners of the Company		2,93.53	4,19.35
<b>Total comprehensive income / (loss) attributable to:</b>			
Owners of the Company		2,93.53	4,19.35
<b>Earnings per equity share</b>			
Basic and diluted earnings per share	24	30.58	43.68

The accompanying notes are an integral part of these financial statements

As per our report of even date attached For and on behalf of the Board

For **CORNELIUS & DAVAR**  
CHARTERED ACCOUNTANTS  
(Firm's Registration No. 101963W)

**B. Akshikar**  
Director  
DIN: 09112346

**J. Chandu**  
Director  
DIN: 09530618

**R. D. DAVAR**  
(PARTNER)  
Membership No. F10620

**R. Mota**  
Company Secretary  
ACS 38473

Place : Mumbai  
Date: May 10, 2023

Place : Mumbai  
Date: May 10, 2023

# BIDDLE SAWYER LIMITED

## Cash Flow Statement for the year ended 31st March, 2023

(₹ in lakhs)

	Year Ended March 31, 2023	Year Ended March 31, 2022
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit/(Loss) before income tax and exceptional items	4,00.70	5,60.48
<b>Adjustments for :</b>		
Provisions written back	-	(0.67)
Interest income classified as investing cash flows	(0.38)	(0.11)
Finance cost	85.68	45.43
<b>Change in operating assets and liabilities</b>		
(Increase)/Decrease in Inventories	(28.68)	1,37.74
Decrease/(Increase) in other assets	11,92.15	(5,55.30)
(Decrease)/Increase in Trade payables	(17,41.68)	6,02.57
(Decrease) in Other liabilities	(93.32)	(16,86.86)
<b>Cash generated from operations</b>	<b>(1,85.53)</b>	<b>(8,96.72)</b>
Income taxes paid (net of refunds)	(1,84.31)	(7.64)
<b>Cash flow before exceptional items</b>	<b>(3,69.84)</b>	<b>(9,04.36)</b>
<b>Net cash (outflow) from operating activities</b>	<b>(3,69.84)</b>	<b>(9,04.36)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
(Purchase) / sale of bank deposits with maturity period more than 3 months but less than 12 months	(1.20)	-
Interest received	1.22	0.03
<b>Net cash inflow from investing activities</b>	<b>0.02</b>	<b>0.03</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from borrowings	3,50.00	14,60.00
Interest paid	-	(44.80)
<b>Net cash inflow from financing activities</b>	<b>3,50.00</b>	<b>14,15.20</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(19.82)</b>	<b>5,10.87</b>
Cash and cash equivalents opening balance	5,39.59	28.72
Cash and cash equivalents closing balance	5,19.77	5,39.59
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(19.82)</b>	<b>5,10.87</b>
<b>NOTES:</b>		
<b>Cash and cash equivalents include:</b>		
Balances with banks	5,19.77	5,39.59
Total cash and cash equivalents	5,19.77	5,39.59

The Cash Flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard-7 on Cash Flow Statements issued by the Institute of Chartered Accountants of India.

As per our report of even date attached

For **CORNELIUS & DAVAR**  
CHARTERED ACCOUNTANTS  
(Firm's Registration No. 101963W)

**R. D. DAVAR**  
(PARTNER)  
Membership No. F10620

Place : Mumbai  
Date: May 10, 2023

For and on behalf of the Board

**B. Akshikar**  
Director  
DIN: 09112346

**J. Chandy**  
Director  
DIN: 09530618

**R. Mota**  
Company Secretary  
ACS 38473

Place : Mumbai  
Date: May 10, 2023

# BIDDLE SAWYER LIMITED

## Statement of Changes in Equity

### (a) Equity share capital

	As at March 31, 2023		As at March 31, 2022	
	No. of Shares	Amount (₹ in lakhs)	No. of Shares	Amount (₹ in lakhs)
Balance at the beginning of the reporting period	9,60,000	96.00	9,60,000	96.00
Changes in equity share capital during the year	-	-	-	-
<b>Balance at the end of the reporting period</b>	<b>9,60,000</b>	<b>96.00</b>	<b>9,60,000</b>	<b>96.00</b>

### (b) Other equity

(₹ in lakhs)

	Reserves and Surplus			Items of Other comprehensive income	Total Other Equity
	Capital reserve	General reserve	Retained Earnings	Remeasurements of the net defined benefit Plans	
<b>Balance at 1 April 2022</b>	<b>2.91</b>	<b>10,06.01</b>	<b>(1,21.41)</b>	-	<b>8,87.51</b>
<b>Total Comprehensive</b>					
Profit/(loss) for the year	-	-	293.53	-	293.53
Other Comprehensive Income for the year	-	-	-	-	-
<b>Transactions with owners of the company</b>					
Dividend on Equity Shares	-	-	-	-	-
<b>Balance at the end of the reporting period March 31, 2023</b>	<b>2.91</b>	<b>10,06.01</b>	<b>1,72.12</b>	-	<b>11,81.04</b>

(₹ in lakhs)

	Reserves and Surplus			Items of Other comprehensive income	Total Other Equity
	Capital reserve	General reserve	Retained Earnings	Remeasurements of the net defined benefit Plans	
<b>Balance at 1 April 2021</b>	<b>2.91</b>	<b>10,06.01</b>	<b>(5,40.76)</b>	-	<b>4,68.16</b>
<b>Total Comprehensive</b>					
Profit/(loss) for the year	-	-	4,19.35	-	4,19.35
Other Comprehensive Income for the year	-	-	-	-	-
<b>Transactions with owners of the company</b>					
Dividend on Equity Shares	-	-	-	-	-
<b>Balance at the end of the reporting period March 31, 2022</b>	<b>2.91</b>	<b>10,06.01</b>	<b>(1,21.41)</b>	-	<b>8,87.51</b>

The accompanying notes are an integral part of these financial statements

As per our report of even date attached

For **CORNELIUS & DAVAR**  
 CHARTERED ACCOUNTANTS  
 (Firm's Registration No. 101963W)

**R. D. DAVAR**  
 (PARTNER)  
 Membership No. F10620

Place : Mumbai  
 Date: May 10, 2023

For and on behalf of the Board

**B. Akshikar**  
 Director  
 DIN: 09112346

**R. Mota**  
 Company Secretary  
 ACS 38473

Place : Mumbai  
 Date: May 10, 2023

**J. Chandy**  
 Director  
 DIN: 09530618

# Notes to the Financial Statements

for the year ended March 31, 2023

## 1 Significant Accounting Policies:

### a) Basis of Accounting

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and relevant provisions of the Companies Act, 2013 ("the Act"). The policies set out below have been consistently applied during the years presented.

The financial statements are presented in INR and all values are rounded to the nearest lakhs (INR 00,000), except where otherwise indicated.

### b) Property, plant and equipment

Freehold land is carried at historical cost. All other items of property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Depreciation is provided on the straight-line method over the estimated useful lives of the assets as per the rates prescribed under:

Schedule II to the Companies Act, 2013 or re-assessed useful life based on technical evaluation as under:

Factory Buildings	30 years
Other Buildings	60 years
Plant and Equipment	10 years
Personal Computers and Laptops	3 to 5 years
Other Computer Equipment	4 years
Furniture and Fixtures	10 years
Office Equipment	5 years
Vehicles	5 years

Depreciation is provided pro-rata for the number of months availability for use. Depreciation on sale / disposal of assets is provided pro-rata up to the end of the month of sale / disposal.

An asset purchased where the actual cost does not exceed ₹ 5,000 is depreciated at the rate of 100%.

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are recognised as income or expense in the statement of profit and loss.

Advances given towards acquisition of Property, plant and equipment outstanding at each balance sheet date are disclosed as Capital Advance under Other non current assets.

### c) Investments and other financial assets

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through profit or loss), and
- those measured at amortised cost.

The classification depends on the Company's business model for managing financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in profit or loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Company has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income.

### d) Inventories

Inventories are valued at lower of cost or net realisable value. Cost is determined on first-in first-out basis. The cost of work-in-progress (other than those lying at third party manufacturing sites which is valued at material cost) and finished goods comprises of raw materials, direct labour, other direct costs and related production overheads, but excludes interest expense. Net realisable value is the estimate

# Notes to the Financial Statements

for the year ended March 31, 2023

of the selling price in the ordinary course of business, less the costs of completion and selling expenses.

## e) Revenue Recognition

Revenue from the sale of goods is recognised when the goods are delivered and titles have passed, at which time all the following conditions are satisfied:

- the company is recognizing revenue as and when it satisfies the performance obligation by transferring promised goods or services to a customer and customer obtains control of the same;
- the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the Company;
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

### Interest Income

Interest income is recorded using the Effective Interest Rate (EIR). Interest income is included in other income in the statement of profit and loss.

## f) Foreign Currency transactions

Items included in the Standalone Financial Statements of the Company are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The Standalone Financial Statements are presented in Indian rupee (INR), which is Company's functional and presentation currency.

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognised in profit or loss.

Foreign exchange gains and losses are presented in the statement of profit and loss on a net basis within other expenses/ other income.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non monetary assets and liabilities such as equity instruments held at fair value through profit or loss are recognised in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equity investments classified as FVOCI are recognised in other comprehensive income. Non-monetary items that are measured based on historical cost in a foreign currency are not translated.

## g) Taxes on Income

Income tax expense represents the sum of the current tax and deferred tax.

Current tax charge is based on taxable profit for the year. Taxable profit differs from profit as reported in the Statement of Profit and Loss because some items of income or expense are taxable or deductible in different years or may never be taxable or deductible. The Company's liability for current tax is calculated using Indian tax rates and laws that have been enacted by the reporting date.

Current tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority.

The Company periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax is the tax expected to be payable or recoverable in the future arising from temporary differences between the carrying amounts of assets and liabilities in the Balance Sheet and the corresponding tax bases used in the computation of taxable profit. It is accounted for using the Balance Sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is

# Notes to the Financial Statements

for the year ended March 31, 2023

probable that taxable profits will be available against which deductible temporary differences can be utilised. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset realised, based on tax rates that have been enacted or substantively enacted by the reporting date.

Deferred income tax assets and liabilities are off-set against each other and the resultant net amount is presented in the Balance Sheet, if and only when the Company currently has a legally enforceable right to set-off the current income tax assets and liabilities.

Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

## h) Provision and contingent liabilities

A provision is recognised if as a result of a past event, the Company has a present obligation (legal or constructive) that can be estimated reliably and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the expenditure required to settle the present obligation at the Balance Sheet date. If the effect of time value of money is material, provisions are discounted using a current pre tax rate that reflects, when appropriate, the risks specific to the liability. The increase in the provision due to passage of time is recognised as an interest expense.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of outflow of resources is remote

## i) Other Accounting Policies

These are consistent with the generally accepted accounting principles.

## 2 Investment Property

(₹ in lakhs)

	As at March 31, 2023	As at March 31, 2022
<b>Gross carrying amount</b>		
Opening gross carrying amount/ Deemed cost	2.08	2.08
Additions (Improvements)	-	-
Deduction	-	-
Closing gross carrying amount	2.08	2.08
<b>Accumulated Depreciation</b>		
Opening Accumulated Depreciation	-	-
Depreciation charge	-	-
<b>Closing Accumulated Depreciation</b>	-	-
Net carrying amount	2.08	2.08

### Estimation of fair value

The Company has a land site that have been considered as Investment Property as it is not currently operational at present. In view of management, the fair market value of the land site is not reliably measurable as there are very few recent transactions of comparable composition of these properties in the market. Further, the fair market value will be subject to numerous municipal deductions dependent upon the current use and intended use of the property. Consequently, it is not possible to ascertain and disclose the range of fair market value. The estimated Ready Reckoner at year end, based on latest published data and current stated use, totals ₹ 13,43.75 lakhs for current year (₹ 24,75.15 lakhs for previous year). Ready Reckoner rates are the prices of the residential property, land or commercial property for a given area that is published and regulated by the respective State Governments as a guide towards payment of stamp duty at the time of transaction. The Ready Reckoner is regarded as a gross value and does not represent the underlying fair market value to the Company.



# Notes to the Financial Statements

for the year ended March 31, 2023

## Note 3 Non current Financial assets - Loans

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Advances recoverable	26.55	26.55
Less: Provision for bad and doubtful loans and advances	(26.55)	(26.55)
	-	-

## Note 3A Non current Financial assets - Others

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Sundry Deposits	15.72	15.72
Less: Provision for bad and doubtful loans and advances	(15.72)	(15.72)
Term deposit with maturity period of more than twelve months	2.65	1.45
	<b>2.65</b>	<b>1.45</b>

## Note 4 Other non-current assets

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Balance with Government Authorities	8,01.88	7,32.38
	<b>8,01.88</b>	<b>7,32.38</b>

## Note 5 Inventories (at lower of cost or net realisable value)

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Raw materials	13,65.83	11,65.15
Packing materials	17.48	17.98
Work-in-progress	54.99	14.76
Finished goods	7,88.60	10,00.33
	<b>22,26.90</b>	<b>21,98.22</b>

## Note 6 Cash and cash equivalents

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Current account Balances with Banks	5,19.77	5,39.59
	<b>5,19.77</b>	<b>5,39.59</b>

## Note 7 Current financial assets - Others

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Interest accrued on investments/ deposits	0.01	0.85
Current account balances with group companies	34.68	12,96.32
	<b>34.69</b>	<b>12,97.17</b>

# Notes to the Financial Statements

for the year ended March 31, 2023

## Note 8 Other current assets

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Balance with Government Authorities	0.08	0.09
Sundry advances	1,15.33	1,15.33
	<b>1,15.41</b>	<b>1,15.42</b>

## Note 9 Share capital

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Equity share capital	96.00	96.00
	<b>96.00</b>	<b>96.00</b>

## Note 10 Other Equity

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
General reserve	10,06.01	10,06.01
Capital reserve	2.91	2.91
Retained earnings	1,72.12	(1,21.41)
	<b>11,81.04</b>	<b>8,87.51</b>

## Note 11 Non current financial liabilities - Borrowings

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Loans from related parties	18,10.00	14,60.00
	<b>18,10.00</b>	<b>14,60.00</b>

## Note 12 Non current financial liabilities - Others

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Security deposits received	0.63	0.63
Other non-current financial liabilities	0.72	0.72
	<b>1.35</b>	<b>1.35</b>

## Note 13 Non-current Provisions

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Drugs Prices Equalisation Account (refer note 16 (i))	71.24	71.24
Provision for pricing of formulation	54.09	54.09
	<b>1,25.33</b>	<b>1,25.33</b>

## Note 14 Trade and other payables

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
Due to Micro, Small and Medium Enterprises	13.49	18.32
Trade and other payables	10,50.71	27,87.56
	<b>10,64.20</b>	<b>28,05.88</b>

# Notes to the Financial Statements

for the year ended March 31, 2023

## Trade Payables Ageing :-

(₹ in lakhs)

	Outstanding as at March 31, 2023						Total
	Unbilled	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	13.49	-	-	-	-	13.49
(ii) Others	4,33.68	1,65.88	4,51.15	-	-	-	10,50.71

(₹ in lakhs)

	Outstanding as at March 31, 2022						Total
	Unbilled	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	18.32	-	-	-	-	18.32
(ii) Others	8,15.73	13,96.02	5,75.81	-	-	-	27,87.56

## Note 15: Other current liabilities

(₹ in lakhs)

	As at March 31, 2023	As at March 31, 2022
Other liabilities	5.94	16.88
Statutory dues	5.93	2.63
	<b>11.87</b>	<b>19.51</b>

## 16 (i) Drugs Prices Equalisation Account

The Company received a letter dated 20th/24th August, 1998 from the Central Government demanding an amount of ₹ 4,40,79,918 comprising ₹ 1,42,74,110 in respect of prices relating to Salbutamol formulations during the period April, 1979 to December, 1983 with interest thereon amounting to ₹ 2,98,05,808 upto 31st July, 1998. The Company had been legally advised that the demand of ₹ 1,42,74,110 is not sustainable and it, therefore follows that the interest demand also cannot be sustained. The total demand has been challenged by the Company in a Writ Petition filed in the Bombay High Court. The Bombay High Court has granted an interim stay of the demand, subject to the Company depositing 50% of the principal amount. Accordingly, the Company has deposited an amount of ₹ 71,50,000 with the Government on 3rd May, 1999. This is a normal interim order passed by the High court in such matters and does not in any way reflect upon the merits or otherwise of the case. The amount will be refunded if the Company succeeds at the final hearing of the matter. The Government's application in the Supreme Court praying that this writ petition be transferred to the Supreme Court from the Bombay High Court was not allowed and the Company's writ petition will now be heard by the Bombay High Court.

## Note 16: Contingent Liabilities

(₹ in lakhs)

	As at March 31, 2023	As at March 31, 2022
Claims against the Company not acknowledged as debts	5912	98.58
Sales tax matters	1996	1996
Guarantee given by the Company to the Customs Authorities	2,00.00	2,00.00
Based on the data obtained by Government, it had directed the Company to pay a tentative amount along with interest due thereon into the Drugs Prices Equalisation Account (DPEA) under Drugs (Price Control) Order 1979, in respect of Bulk Drug Amoxicillin Trihydrate, on account of alleged unintended benefit enjoyed by the Company. The Company had filed its reply contending that no amount is payable into DPEA.	49.29	49.29

# Notes to the Financial Statements

for the year ended March 31, 2023

## Note 17: Share Capital

	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
<b>Authorised</b>		
15,00,000 (Previous year : 15,00,000) Equity Shares of ₹10 each	1,50.00	1,50.00
<b>ISSUED, SUBSCRIBED &amp; PAID-UP:</b>		
9,60,000 (Previous year : 9,60,000) Equity Shares of ₹10 each fully paid up (of the above 7,50,000 ordinary shares have been allotted as fully paid-up Bonus shares by capitalisation of General Reserve)	96.00	96.00
<b>TOTAL</b>	<b>96.00</b>	<b>96.00</b>
<b>a) Shares held by holding company</b>		
Equity Shares of ₹ 10 each 9,60,000 (Previous year : 9,60,000) held by GlaxoSmithKline Pharmaceuticals Limited, the Holding Company	96.00	96.00

	As at March 31, 2023		As at March 31, 2022	
	Number of Shares	₹ In Lakhs	Number of Shares	₹ In Lakhs
<b>a) Reconciliation of the number of shares</b>				
Balance at the beginning of the year	9,60,000	96.00	9,60,000	96.00
Issued during the year	-	-	-	-
Balance at the end of the year	9,60,000	96.00	9,60,000	96.00

### b) Rights, preferences and restrictions attached to equity shares:

The Company has only one class of equity shares having a par value of ₹ 10/- per share. Each shareholder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

### c) Details of shareholders holding more than 5% shares in the company:

	As at March 31, 2023	As at March 31, 2022
	Number of Shares	Number of Shares
GlaxoSmithKline Pharmaceuticals Limited, the Holding Company	9,60,000 {100%}	9,60,000 {100%}

## Note 18: Revenue from operations

	(₹ in lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
<b>A. Sale of products (gross)</b>		
Sale of products	51,31.09	80,66.00
	<b>51,31.09</b>	<b>80,66.00</b>
<b>B. Other operating revenue</b>		
Others	-	16.46
	-	<b>16.46</b>
<b>Total Revenue from operations</b>	<b>51,31.09</b>	<b>80,82.46</b>

## Note 19: Other income

	(₹ in lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Interest income	0.38	0.11
Provisions written back (net)	-	0.67
Miscellaneous Income	-	0.01
	<b>0.38</b>	<b>0.79</b>

# Notes to the Financial Statements

for the year ended March 31, 2023

## Note 20: Cost of materials consumed

	(₹ in lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Cost of materials consumed	33,13.53	58,70.57
	<b>33,13.53</b>	<b>58,70.57</b>

## Note 21: Changes In Inventories Of Finished Goods, Work-In-Progress and traded goods

	(₹ in lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Opening stock		
Work-in-progress	14.76	23.98
Finished goods	10,00.33	11,65.82
Less: Closing stock		
Work-in-progress	54.99	14.76
Finished goods	788.60	10,00.33
	<b>1,71.50</b>	<b>1,74.71</b>

## Note 22: Finance costs

	(₹ in lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Interest cost on financial liabilities measured at amortized cost	85.68	45.43
	<b>85.68</b>	<b>45.43</b>

## Note 23: Other expenses

	(₹ in lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Manufacturing charges	898.41	13,03.40
Rates and taxes	0.04	9.55
Statutory audit fees	5.59	5.59

(₹ in lakhs)

	Year ended March 31, 2023	Year ended March 31, 2022
In other capacity in respect of :		
Tax audit fees	1.05	1.05
Exchange loss (net)	1,06.37	-
Reimbursement of expenses to GlaxoSmithKline Pharmaceuticals Limited	61.43	61.46
Tax and consulting fees	13.74	17.31
Security guard services	24.91	24.76
Third party warehousing	2.31	4.57
Miscellaneous expenses	46.21	4.37
	<b>11,60.06</b>	<b>14,32.06</b>

## Note 24: Earnings Per Share

	Year ended March 31, 2023	Year ended March 31, 2022
Earnings per share is calculated by dividing the profit attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. The numbers used in calculating basic and diluted earnings per equity share are as stated below:		
Profit /(loss) after taxation (₹ Lakhs)	293.53	4,19.35
Weighted average number of shares (Nos)	960,000	960,000
Earnings per share (Basic and Diluted) - ₹	30.58	43.68
Face value per share - ₹	10.00	10.00

# Notes to the Financial Statements

for the year ended March 31, 2023

## Note 25: Tax expense

### (a) Amounts recognised in profit and loss

	(₹ in lakhs)	
	For the year ended March 31, 2023	For the year ended March 31, 2022
Current income tax	1,0717	31.88
Deferred tax		
Decrease/(Increase) in deferred tax assets	-	1,09.25
Adjustment to deferred tax attributable to change in Income Tax rates	-	-
<b>Tax expense for the year</b>	<b>1,07.17</b>	<b>1,41.13</b>

### (b) Reconciliation of effective tax rate

	(₹ in lakhs)	
	For the year ended March 31, 2023	For the year ended March 31, 2022
Profit /(loss) before tax	4,00.70	5,60.48
Tax using the Company's domestic tax rate at 25.168% (Previous Year: 25.168%)	1,00.87	1,41.06
Tax effect of:		
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:		
Other items	6.30	0.07
	<b>1,07.17</b>	<b>1,41.13</b>

The Company's effective tax rate for the years ended March 31, 2023 is 26.75% (financial year 2021-22 - 25.18%). Income tax expense was ₹ 1,07.17 lakhs for the year ended March 31, 2023 and ₹ 1,41.13 lakhs for the year ended March 31, 2022.

### (c) Movement in deferred tax balances

	(₹ in lakhs)			
	March 31, 2023			
	Net balance April 1, 2022	Recognised in profit or loss	Recognised in OCI	Net Deferred tax asset / (liability)
<b>Deferred tax asset</b>				
Expenses allowable for tax purpose when paid	22.99	-	-	22.99
Provision for pricing matters	13.43	-	-	13.43
<b>Tax assets (Liabilities)</b>	<b>36.43</b>	<b>-</b>	<b>-</b>	<b>36.43</b>

	(₹ in lakhs)			
	March 31, 2022			
	Net balance April 1, 2021	Recognised in profit or loss	Recognised in OCI	Net Deferred tax asset / (liability)
<b>Deferred tax asset</b>				
Expenses allowable for tax purpose when paid	1,32.24	(1,09.25)	-	22.99
Provision for pricing matters	13.43	-	-	13.43
<b>Tax assets (Liabilities)</b>	<b>1,45.68</b>	<b>(1,09.25)</b>	<b>-</b>	<b>36.43</b>

### (d) The details of income tax assets and income tax liabilities as at March 31, 2023 and March 31, 2022

	(₹ in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
Current Tax Assets (Net)	5,49.98	4,72.84
Current Tax Liabilities (Net)	-	-
<b>Net current income tax asset/(liability) at the end</b>	<b>5,49.98</b>	<b>4,72.84</b>

# Notes to the Financial Statements

for the year ended March 31, 2023

The gross movement in the current tax asset/(liability) for the year ended March 31, 2023 and March 31, 2022 is as follows:

	(₹ in lakhs)	
	Year ended	
	March 31, 2023	March 31, 2022
Net current income tax asset/(liability) at the beginning	4,72.84	4,97.08
Income tax Paid	1,84.31	7.64
Refund received during the year		
Current Income Tax Expense	(1,07.17)	(31.88)
Tax Adjustment of earlier years		
<b>Net current income tax asset/(liability) at the end</b>	<b>5,49.98</b>	<b>4,72.84</b>

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

Significant management judgement is required in determining provision for income tax, deferred income tax assets and liabilities and recoverability of deferred income tax assets. The recoverability of deferred income tax assets is based on estimates of taxable income in which the relevant entity operates and the period over which deferred income tax assets will be recovered.

## Note 26: Financial instruments – Fair values and risk management

### A. Accounting classification and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities including their levels presented below.

	(₹ in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
<b>Financial assets at amortised cost</b>		
Cash and cash equivalents	5,19.77	5,39.59
Other bank balance	2.65	1.45
Current account balances with group companies	34.68	12,96.32
Interest accrued on investments/ deposits	0.01	0.85
<b>Total financial assets</b>	<b>5,57.11</b>	<b>18,38.21</b>
<b>Financial liabilities at amortised cost</b>		
Security deposits received	0.63	0.63
Other non-current financial liabilities	0.72	0.72
Trade payables	10,64.20	28,05.88
Loans from related parties	18,10.00	14,60.00
<b>Total financial liabilities</b>	<b>28,75.55</b>	<b>42,67.23</b>

### B. Fair Value Hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are measured at amortised cost and for which fair values are disclosed in the Standalone Financial Statements.

#### Fair value of financial assets and liabilities measured at amortised cost

The amount of fair value of the above Financial assets and liabilities is considered to be insignificant in value and hence carrying value and the fair value is considered to be same.

The carrying amounts of Cash and cash equivalents, other bank balance, Trade receivables, Trade payables, balance with group companies, accrued interest, loan from related parties are considered to be the same as their fair values due to their short term nature.

# Notes to the Financial Statements

for the year ended March 31, 2023

## C. Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- Liquidity risk
- Market risk

### Risk management framework

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Board of Directors has established the Risk Management Committee, which is responsible for developing and monitoring the Company's risk management policies. The committee reports regularly to the Board of Directors on its activities

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee of the Holding company oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

### Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

The Company's principal sources of liquidity are cash and cash equivalents and the cash flow that is generated from operations. The Company has no outstanding bank borrowings. The Company believes that the working capital is sufficient to meet its current requirements. Any short-term surplus cash generated, over and above the amount required for working capital management and other operational requirements, are retained as Cash and Investment in short term deposits with banks. The said investments are made in instruments with appropriate maturities and sufficient liquidity.

As of March 31, 2023, the Company had working capital of ₹ 18,20.7 lakhs, including cash and cash equivalents of ₹ 5,19.77 lakhs, investments in term deposits (i.e., bank certificates of deposit having original maturities of more than 3 months and less twelve months) of ₹ nil.

As of March 31, 2022, the Company had working capital of ₹ 13,25.01 lakhs, including cash and cash equivalents of ₹ 5,39.59 lakhs, investments in term deposits (i.e., bank certificates of deposit having original maturities of more than 3 months and less twelve months) of ₹ nil.

### Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.

(₹ in lakhs)

As at March 31, 2023	Contractual cash flows					
	Carrying amount	Total	1 year or less	1-2 years	2-5 years	More than 5 years
<b>Non-derivative financial liabilities</b>						
Trade Payables and other payables	10,64.20	10,64.20	10,64.20	-	-	-
Security deposits	0.63	0.63	-	-	0.63	-
Other non-current liabilities	0.72	0.72	-	-	0.72	-



# Notes to the Financial Statements

for the year ended March 31, 2023

(₹ in lakhs)

As at March 31, 2022	Contractual cash flows					
	Carrying amount	Total	1 year or less	1-2 years	2-5 years	More than 5 years
<b>Non-derivative financial liabilities</b>						
Trade Payables and other payables	28,05.88	28,05.88	28,05.88	-	-	-
Security deposits	0.63	0.63	-	-	0.63	-
Other non-current liabilities	0.72	0.72	-	-	0.72	-

## Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates and foreign currency exchange rates) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables. The Company is exposed to market risk primarily related to foreign exchange rate risk.

## Currency risk

The fluctuation in foreign currency exchange rates may have potential impact on the profit and loss account, where any transaction references more than one currency or where assets/liabilities are denominated in a currency other than the functional currency of the entity.

The Company is exposed to currency risk on account of its receivables and payables in foreign currency. The functional currency of the Company is Indian Rupee.

## Exposure to currency risk

The Company's exposure to foreign currency risk at the end of the reporting period is as follows:

	(₹ in lakhs)			
	As at March 31, 2023		As at March 31, 2022	
	USD	GBP	USD	GBP
Trade payables	(3,15.85)	-	-	-
Current financial assets - Others		34.68		12,96.32
Net statement of financial position exposure	(3,15.85)	34.68	-	12,96.32

## Sensitivity analysis

A reasonably possible strengthening / weakening of the respective foreign currencies with respect to functional currency of Company would result in increase or decrease in profit or loss and equity as shown in table below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases. The following analysis has been worked out based on the exposures as of the date of statements of financial position.

Effect in Lakhs	Strengthening / Weakening %	Profit or loss		Equity	
		Strengthening	Weakening	Strengthening	Weakening
<b>March 31, 2023</b>					
USD	5%	(15.79)	15.79	-	-
GBP	5%	1.73	(1.73)	-	-

Effect in Lakhs	Strengthening / Weakening %	Profit or loss		Equity	
		Strengthening	Weakening	Strengthening	Weakening
<b>March 31, 2022</b>					
GBP	5%	64.82	(64.82)	-	-

(Note: The impact is indicated on the profit/loss before tax basis)

# Notes to the Financial Statements

for the year ended March 31, 2023

## 27 Capital Management

### (a) Risk Management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders.

The Company has adequate cash and bank balances and has interest bearing liabilities. The Company monitors its capital by a careful scrutiny of the cash and bank balances, a regular assessment of any debt requirements and the maintenance of debt equity ratio and debt service coverage ratio etc. (Refer Note 31)

## 28 SEGMENT REPORTING

An operating segment is one whose operating results are regularly reviewed by the entity's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The Company has identified the Chief Operating Decision Maker as its Director. The Chief Operating Decision Maker reviews performance of pharmaceutical business on an overall basis. As the Company has a single reportable segment, the segment wise disclosure requirements of Ind AS 108 on Operating Segment is not applicable. In compliance to the said standard, Entity-Wide disclosures are as under :

	(₹ in lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Revenues from external customers attributed to the country of domicile and attributed to all foreign countries from which the company derives revenues		
Revenue from the Country of Domicile-India	6,33.29	6,82.01
Revenue from foreign countries	44,97.80	74,00.45
<b>Total</b>	<b>51,31.09</b>	<b>80,82.46</b>

(₹ in lakhs)

	As at March 31, 2023	As at March 31, 2022
<b>Details of non current asset</b>		
Non Current asset from the Country of Domicile- India	13,53.94	12,07.30
Non Current asset from foreign countries	-	-
<b>Total</b>	<b>13,53.94</b>	<b>12,07.30</b>

## 29 Related Party Disclosures

- 1 Related parties with whom there were transactions during the year are listed below:

Holding Company:

- The Company is a wholly owned subsidiary of GlaxoSmithKline Pharmaceuticals Limited.

Other related parties in the GlaxoSmithKline (GSK) Group where common control exists

- GSK Export Limited
- GlaxoSmithKline Pharma India Private Limited

- 2 The following transactions were carried out with the related parties at normal commercial terms in the ordinary course of business.

	Holding Company	
	Year ended March 31, 2023	Year ended March 31, 2022
	<b>GlaxoSmithKline Pharmaceuticals Limited</b>	
1. Payment of common costs	61.43	61.46
2. Sale of products	6,33.29	6,65.55
3. Payment of Manufacturing charges	8,98.41	13,03.40
4. Interest on loan taken	85.54	44.80
5. Borrowings	18,10.00	14,60.00
6. Outstanding receivable / (Payable) by the Company (net)*	(1,41.97)	(4,18.28)

# Notes to the Financial Statements

for the year ended March 31, 2023

	Other related parties in the GlaxoSmithKline (GSK) Group where common control exists	
	Year ended March 31, 2023	Year ended March 31, 2022
	<b>GSK Export Limited</b>	
1. Sale of products	44,97.80	74,00.45
2. Outstanding receivable / (Payable) by the Company (net)*	34.68	12,96.32

\* Transactions with the above parties are accounted in the respective current accounts.

## 30 Disclosures as required by Micro, Small and Medium Enterprises Development Act, 2006 are as under:

Particulars	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
(a) The principal amount and the interest due thereon remaining unpaid to suppliers		
(i) Principal	13.49	17.69
(ii) Interest due thereon	0.10	0.63
	<b>13.59</b>	<b>18.32</b>

Particulars	(₹ in lakhs)	
	As at March 31, 2023	As at March 31, 2022
(b) (i) The delayed payments of principal amount paid beyond the appointed date during the entire accounting year	2.88	1,23.43
(ii) Interest actually paid under Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006	-	-
(c) (i) Normal Interest accrued during the year, for all the delayed payments, as per the agreed terms	-	-
(ii) Normal Interest payable for the period of delay in making payment, as per the agreed terms	-	-
(d) (i) Total Interest accrued during the year	0.10	0.63
(ii) Total Interest accrued during the year and remaining unpaid	0.10	0.63

The above information regarding Micro, Small and Medium enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company.

## 31 Key Financial Ratios

	Ratio	Numerator	Denominator	Mar-23	Mar-22	Variance	Reason for variance
1	Current Ratio	Current assets	Current Liabilities	2.69	1.47	83%	Due to improvement in working capital on account of reduction in trade payables
2	Return on Equity	Profit after tax	Shareholders Equity	22.99%	42.64%	-46%	Decrease in sales resulted in decrease in profits.
3	Inventory Turnover Ratio	Sale of Products	Average inventories	2.32	3.56	-35%	Decrease in sales resulted in decrease in profits.
4	Trade Payables Turnover Ratio	Cost of Goods Sold + Expenses	Average trade payables	2.40	2.98	-20%	
5	Net Capital Turnover Ratio	Sale of Products	Working Capital	2.82	6.09	-54%	Decrease in sales resulted in decrease in profits.
6	Net Profit Ratio	Profit after tax	Revenue from operations	6%	5.19%	10%	
7	Return on Capital Employed	Profit before interest and tax	Net Worth	38.09%	61.61%	-38%	Decrease in sales resulted in decrease in profits.

# Notes to the Financial Statements

for the year ended March 31, 2023

	Ratio	Numerator	Denominator	Mar-23	Mar-22	Variance	Reason for variance
8	Debt Equity Ratio	Debt	Total Equity	1.42	1.48	-5%	
9	Debt service coverage ratio	Net profit before tax plus interest cost minus non-operating income and non cash income	Interest+ Outstanding Loans	0.26	0.40	-36%	Loan from Parent company taken in current year

The Trade receivable Turnover ratio is not applicable to the company as all of the trade receivables are Group Companies which are disclosed under other current financial assets.

The Return on Investment ratio is also not applicable to the company

## 32 : Additional information

- (i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (iii) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
  - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
  - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (iv) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
  - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
  - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (v) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

**33** In view to make financial statements comparable, previous period's figures have been regrouped wherever necessary.

As per our report of even date attached

For **CORNELIUS & DAVAR**  
 CHARTERED ACCOUNTANTS  
 (Firm's Registration No.101963W)

**R. D. DAVAR**  
 (PARTNER)  
 Membership No. F10620

Place : Mumbai  
 Date: May 10, 2023

For and on behalf of the Board

**B. Akshikar**  
 Director  
 DIN: 09112346

**R. Mota**  
 Company Secretary  
 ACS 38473

Place : Mumbai  
 Date: May 10, 2023

**J. Chandy**  
 Director  
 DIN: 09530618